ArticleSexually transmitted diseases2026
Dual Treponemal and Non-Treponemal Rapid Test for Syphilis in People Living with HIV: A Diagnostic Accuracy Study.
Article in Sexually transmitted diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Innovations and Challenges in Syphilis Screening and Prevention Among Men Who Have Sex With Men: A Scoping Review.Sexually transmitted diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundRapid dual treponemal/non-treponemal (lipoidal antigen) tests could improve syphilis detection strategies among people living with human immunodeficiency virus (PLHIV). The World Health Organization (WHO) recommends minimum performance targets for syphilis point-of-care tests: sensitivity >80% for the treponemal component, >95% for the non-treponemal component, and specificity >90% for both. We evaluated the diagnostic accuracy of a dual treponemal/non-treponemal test in PLHIV.
methodsCross-sectional study using stored serum samples donated by PLHIV who had been previously enrolled in a study conducted in Cali, Colombia. The index test was the Dual Path Platform® Syphilis Screen & Confirm Assay (DPP-SSCA, Chembio Diagnostic Systems, Inc.). A combination of Treponema pallidum hemagglutination assay and treponemal enzyme-linked immunosorbent assay (ELISA) served as the reference standard for the treponemal component, and the rapid plasma reagin (RPR) test for the non-treponemal component. We estimated the sensitivity and specificity of both components.
resultsWe performed 280 DPP-SSCA on serum from 220 PLHIV (60 samples tested in duplicate). Median age: 35.2 years; 75.9% male; 53.0% with undetectable viral load; and 35.9% with previously treated syphilis. The treponemal component had 74.5% sensitivity (95% confidence interval [CI], 58.4-85.9) and 97.2% specificity (95% CI, 92.8-98.9). The non-treponemal component had 90.4% sensitivity (95% CI, 74.9-96.7) and 46.5% specificity (95% CI, 38.0-55.3).
conclusionsIn PLHIV, the serum-based DPP-SSCA did not meet WHO performance targets. Given the low specificity of the non-treponemal component, the development of improved diagnostic tools and rigorous validation are needed to ensure reliable and rapid diagnosis of active syphilis infection in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.